Cargando…

Assessment of serum CXCL9 and pentraxin 3 as novel markers for hepatocellular carcinoma in cirrhotic hepatitis C patients

AIM OF THE STUDY: Hepatocellular carcinoma (HCC) is the most frequent primary cancer of the liver. It is also one of the world’s most common cancers and an important leading cause of cancer mortality in many parts of the world. As a result, it is essential to look for efficient markers for early and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mehanna, Rafik Gabbour, Mohiedeen, Khaled, Kassem, Mohamed, Deghady, Akram, Abouelkheir, Hossam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2023
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090998/ https://www.ncbi.nlm.nih.gov/pubmed/37064830 http://dx.doi.org/10.5114/ceh.2023.125255

Ejemplares similares

Serum pentraxin 3 as a biomarker of hepatocellular carcinoma in chronic hepatitis B virus infection
por: Deng, Huan, et al.
Publicado: (2020)

Galectin-3 is not useful for hepatocellular carcinoma surveillance in cirrhotic patients but it may be a marker of cirrhosis development
por: Nassar, Eman Saad, et al.
Publicado: (2021)

CXCL8, CXCL9, and CXCL10 serum levels increase in syphilitic patients with seroresistance
por: Dong, Xiaoyan, et al.
Publicado: (2021)

Serum pentraxin 3 concentrations in neonates
por: Lannergård, Anders, et al.
Publicado: (2014)

Increased Serum Pentraxin 3 Levels are Associated with Poor Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma
por: Han, Qunying, et al.
Publicado: (2021)

Hypermethylation of DNA Methylation Markers in Non-Cirrhotic Hepatocellular Carcinoma
por: Fu, Siyu, et al.
Publicado: (2023)

Serum vascular endothelial growth factor as a tumor marker for hepatocellular carcinoma in hepatitis C virus-related cirrhotic patients
por: Alzamzamy, Ahmed, et al.
Publicado: (2021)

Pentraxins as Key Disease Markers for Periodontal Diagnosis
por: Kathariya, Rahul, et al.
Publicado: (2013)

Serum CXCL9 as a potential marker of Type 1 inflammation in the context of eosinophilic asthma
por: Hasegawa, Takehiro, et al.
Publicado: (2019)

Prognostic and diagnostic value of SOX9 in cirrhotic and noncirrhotic hepatocellular carcinoma
por: Xu, Zhong-Ping, et al.
Publicado: (2021)

Pentraxin 3 as a Novel Marker in Cardiovascular Diseases?
por: Malinowski, Bartosz, et al.
Publicado: (2011)

CXCL8, CXCL9, CXCL10, and CXCL11 as biomarkers of liver injury caused by chronic hepatitis B
por: Yu, Xin, et al.
Publicado: (2022)

Pentraxin 3 as a marker of vasospasm following subarachnoid hemorrhage
por: Zanier, ER, et al.
Publicado: (2008)

IP-10/CXCL10 and MIG/CXCL9 as novel markers for the diagnosis of lymphoma-associated hemophagocytic syndrome
por: Maruoka, Hayato, et al.
Publicado: (2013)

Plasma chemokines CXCL10 and CXCL9 as potential diagnostic markers of drug-sensitive and drug-resistant tuberculosis
por: Sampath, Pavithra, et al.
Publicado: (2023)

Serum Pentraxin-3 Levels Are Associated with the Severity of Metabolic Syndrome
por: Karakas, Mehmet Fatih, et al.
Publicado: (2013)

Circulating Profiles of Serum Proguanylin, S100A12 Protein and Pentraxin 3 as Diagnostic Markers of Ulcerative Colitis
por: Kałużna, Aleksandra, et al.
Publicado: (2023)

Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients
por: Feder, Susanne, et al.
Publicado: (2020)

Role of serum CXCL9 and CXCL13 in predicting infection after kidney transplant: A STROBE study
por: Yan, Lin, et al.
Publicado: (2021)

Clinicopathological and prognostic significance of PKM2 protein expression in cirrhotic hepatocellular carcinoma and non-cirrhotic hepatocellular carcinoma
por: Liu, Yan, et al.
Publicado: (2017)

Plasma Pentraxin3 is a Novel Marker for Nonalcoholic Steatohepatitis (NASH)
por: Yoneda, Masato, et al.
Publicado: (2008)

Pentraxin-3 as a Marker of both the Presence and the Severity of Metabolic Syndrome
por: Canpolat, Uğur, et al.
Publicado: (2014)

The long pentraxin PTX3: a novel serum marker to improve the prediction of osteoporosis and osteoarthritis bone-related phenotypes
por: Visconti, Virginia Veronica, et al.
Publicado: (2021)

Correction to: The long pentraxin PTX3: a novel serum marker to improve the prediction of osteoporosis and osteoarthritis bonerelated phenotypes
por: Visconti, Virginia Veronica, et al.
Publicado: (2021)

Serum CXCL5 Detects Early Hepatocellular Carcinoma and Indicates Tumor Progression
por: Laschtowitz, Alena, et al.
Publicado: (2023)

Low serum magnesium concentration is associated with the presence of viable hepatocellular carcinoma tissue in cirrhotic patients
por: Parisse, Simona, et al.
Publicado: (2021)

Hepatocellular Carcinoma Arising in Non-Cirrhotic Haemochromatosis
por: Thompson, N. P., et al.
Publicado: (1995)

Segmental Distribution of Hepatocellular Carcinoma in Cirrhotic Livers
por: Renzulli, Matteo, et al.
Publicado: (2022)

Overproduction of CXC chemokines CXCL1, CXCL9, CXCL10 and CXCL12 in β-thalassemia major or patients
por: Najmaddini, Hamid, et al.
Publicado: (2014)

CXCL9 concentrations in cerebrospinal fluid and serum of patients with tick-borne encephalitis
por: Koper, Olga M., et al.
Publicado: (2016)

Measurement of procalcitonin in bronchoalveolar lavage and serum as early predictors in acute respiratory distress syndrome
por: Razek, A Abdel, et al.
Publicado: (2008)

Genetic Polymorphism of Epidermal Growth Factor Gene as a Predictor of Hepatocellular Carcinoma in Hepatitis C Cirrhotic Patients
por: Baghdadi, Ibrahim, et al.
Publicado: (2020)

Pentraxin-3, procalcitonin and lactate as prognostic markers in patients with sepsis and septic shock
por: Hu, Chenggong, et al.
Publicado: (2017)

Long pentraxin 3 as a marker of COVID-19 severity: evidences and perspectives
por: Assandri, Roberto, et al.
Publicado: (2022)

The Role of Serum Cytokines in the Pathogenesis of Hepatic Osteodystrophy in Male Cirrhotic Patients
por: Soylu, Ali Riza, et al.
Publicado: (2012)

Morbidity and Mortality After Major Hepatic Resection in Cirrhotic Patients With Hepatocellular Carcinoma
por: Nagasue, Naofumi, et al.
Publicado: (1988)

ICG Clearance in Assessing Cirrhotic Patients with Hepatocellular Carcinoma for Major Hepatic Resection
por: Kitano, Seigo, et al.
Publicado: (1997)

Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements
por: Perisetti, Abhilash, et al.
Publicado: (2021)

Nitro-oxidative stress, VEGF and MMP-9 in patients with cirrhotic and non-cirrhotic portal hypertension
por: MUTI, LEON ADRIAN, et al.
Publicado: (2015)

Serum interleukin-35 and pentraxin-3 levels in patients with mild acute pancreatitis
por: Aksoy, Evrim Kahramanoğlu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i9qkanvkmmfn9oir1oopd1eem6